Initiator Pharma: Positive Topline Data for IPTN2021 - Redeye

Following the completion of the first clinical Proof-of-Principle (PoP) study in the IPTN2021 program, Initiator Pharma today announced that an analysis of the first data read-out has been obtained. The candidate demonstrated a statistically significant pain-reducing effect with limited side effects.

Länk till analysen i sin helhet: https://www.redeye.se/research/843052/initiator-pharma-positive-topline-data-for-iptn2021?utm_source=finwire&utm_medium=RSS